Atommap - About the company
Atommap is a series C company based in New York City (United States), founded in 2023 by Jesus Izaguirre and Yujie Wu. It operates as a Provider of physics-based and ML-augmented computational drug discovery platform. Atommap has raised $31.1M in funding. The company has 136 active competitors, including 42 funded and 13 that have exited. Its top competitors include companies like Seer, Biognosys and Peptris.
Company Details
Provider of physics-based and ML-augmented computational drug discovery platform. It offers Silicon Therapeutics and Roivant Discovery to deliver STING agonist, potent inhibitors against oncology target, and active molecules for therapeutic degradation of target proteins.
- Website
- www.atommap.com/
- Social
- Email ID
- *****@atommap.com
Key Metrics
Founded Year
2023
Location
New York City, United States
Stage
Series C
Total Funding
$31.1M in 1 round
Latest Funding Round
Ranked
21st among 136 active competitors
Employee Count
19 as on Mar 31, 2026
Sign up to download Atommap's company profile
Atommap's funding and investors
Atommap has raised a total funding of $31.1M over 1 round.
Here is the list of recent funding rounds of Atommap:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Mar 06, 2026 | 6534943 | Series C | 3012633 | 9652774 | 2553195 | 1736003 |
Access funding benchmarks and valuations. Sign up today!View details of Atommap's funding rounds and investors
Atommap's founders and board of directors
Founder? Claim ProfileThe founders of Atommap are Jesus Izaguirre and Yujie Wu.
Here are the details of Atommap's key team members:
- Jesus Izaguirre: Co-Founder of Atommap. Contact Info: 1 email address
- Yujie Wu: Co-Founder & CTO of Atommap. Contact Info: 1 email address
View details of Atommap's Founder profiles and Board Members
Atommap's employee count trend
Atommap has 19 employees as of Mar 26. Here is Atommap's employee count trend over the years:
Uncover Atommap's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Atommap's Competitors and alternates
Top competitors of Atommap include Seer, Biognosys and Peptris. Here is the list of Top 10 competitors of Atommap, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Seer 2017, San Francisco (United States), Public | Developer of proteomics platform for early detection of cancer and neurological diseases | $128M | 72/100 | |
2nd | Biognosys 2008, Schlieren (Switzerland), Acquired | Provider of proteomics service | $9.13M | 63/100 | |
3rd | Provider of AI-based proteomic data analysis software for drug discovery | $9.17M | 60/100 | ||
4th | Talus 2020, Seattle (United States), Seed | Provider of drug discovery platform for gene regulators | $19.8M | 60/100 | |
5th | _1558516543928.png?devicePixelRatio=2&height=30&width=30){kind=logo} Unnatural Products 2016, Santa Cruz (United States), Series B | Developer of computational biology techniques platform to engineer peptides for undruggable targets | $83M | 57/100 | |
6th |  BridGene Biosciences 2018, Sunnyvale (United States), Series B | Developer of small-molecule drugs for the treatment of cancer | $78.5M | 57/100 | |
7th |  Atavistik 2021, Cambridge (United States), Series B | Developer of allosteric therapeutics for precision oncology and rare diseases | $260M | 55/100 | |
8th | Avenue Biosciences 2023, Palo Alto (United States), Seed | Biotechnology company that employs protein engineering solutions | $15.6M | 54/100 | |
9th |  Grove Biopharma 2020, Chicago (United States), Series A | Developer of AI-based drug modality platform for protein-based drugs | $34M | 54/100 | |
10th | ProteinSimple 2004, San Jose (United States), Acquired | Provider tools to help researchers with protein analysis | $94.3M | 54/100 | |
21st |  Atommap 2023, New York City (United States), Series C | Provider of physics-based and ML-augmented computational drug discovery platform | $31.1M | - | 43/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Atommap's competitors? Click here to see the top ones
Atommap's Investments and acquisitions
Atommap has made no investments or acquisitions yet.
Reports related to Atommap
Here is the latest report on Atommap's geography:
Are you a Founder ?
FAQs about Atommap
Explore our recently published companies
- Paykal - Mumbai based, 2019 founded, Unfunded company
- BCN Retail - Japan based, 1981 founded, Unfunded company
- Vistello - Unfunded company
- PV Lumens - Mumbai based, 2012 founded, Unfunded company
- Blast Studio - London based, 2018 founded, Unfunded company
- Milk Road - Toronto based, 2022 founded, Unfunded company
